New combo therapy shows promise for tough lymphoma
NCT ID NCT07236151
First seen Nov 19, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tested a new treatment for adults with large B-cell lymphoma that returned or didn't respond to prior therapy. Participants received a stem cell transplant followed by two types of CAR-T cells (CD19 and CD22) to attack the cancer. The goal was to see if this approach could improve complete remission rates and monitor side effects. 23 people took part in this completed Phase 2 trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
Conditions
Explore the condition pages connected to this study.